L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 548.3 ILS -0.81% Market Closed
Market Cap: 433.6m ILS

During the last 3 months Lineage Cell Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 31% over this period (open performance analysis).

The last transaction was made on Jan 27, 2025 by Broadwood Partners, L.p. , who bought 6m ILS worth of LCTX shares.

Last Transactions:
Broadwood Partners, L.p.
₪+6m
Howe Jill Ann
₪+8.9k
Samuel George A. Iii
₪+9k
Mulroy Michael H.
₪+22.6k
Culley Brian M
₪+24k
Howe Jill Ann
₪+9.3k
Culley Brian M
₪+10.5k
Bailey Don M
₪+100k
Broadwood Partners, L.p.
₪+7m
Jayasuriya Anula
₪+10.9k
Culley Brian M
₪+9.8k
Amin Dipti
₪+57.1k
Culley Brian M
₪+7.2k
Broadwood Partners, L.p.
₪+678k
Broadwood Partners, L.p.
₪+284.3k
Mulroy Michael H.
₪+9.8k
Broadwood Partners, L.p.
₪+355.3k
Hogge Gary S.
₪-23k
Hogge Gary S.
₪-1.2m
Russell Angus C.
₪-14k
Andrews Deborah J
₪-56.1k
Culley Brian M
₪-1.3m
Hernandez Alexandra
₪-13.4k
Broadwood Partners, L.p.
₪+12.7k
Broadwood Partners, L.p.
₪+1.4k
Broadwood Partners, L.p.
₪+9.9k
Roberts Brandi
₪+5.1k
Leavitt Chase C.
₪+5.1k
Culley Brian M
₪+10.1k
Andrews Deborah J
₪+3.8k
Bradsher Neal C
₪+7m
Skibsted Russell
₪+5.3k
View All Transactions

During the last 3 months Lineage Cell Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 31% over this period (open performance analysis).

The last transaction was made on Jan 27, 2025 by Broadwood Partners, L.p. , who bought 6m ILS worth of LCTX shares.

Sold
0-3
months
0 ILS
0
3-6
months
0 ILS
0
6-9
months
0 ILS
0
9-12
months
0 ILS
0
Bought
0-3
months
No Insider Transactions
0
0 ILS
3-6
months
No Insider Transactions
0
0 ILS
6-9
months
No Insider Transactions
0
0 ILS
9-12
months
1
6m ILS

Lineage Cell Therapeutics Inc
Insider Trading Chart

Lineage Cell Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Lineage Cell Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Lineage Cell Therapeutics Inc
Glance View

Market Cap
433.6m ILS
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

LCTX Intrinsic Value
512.97 ILS
Overvaluation 6%
Intrinsic Value
Price
L

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top